产品
编 号：F351725
分子式：C20H18O4
分子量：322.35
分子式：C20H18O4
分子量：322.35
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 41060-15-5
产品详情
生物活性：
Neobavaisoflavone, a flavonoid, is isolated from the seeds of Psoralea corylifolia. Neobavaisoflavone exhibits anti-inflammatory, anti-cancer and anti-oxidation activities. Neobavaisoflavone inhibits DNA polymerase at moderate to high concentrations. Neobavaisoflavone also inhibits platelet aggregation.
体内研究：
Neobavaisoflavone (30 mg/kg; i.p. for 6 weeks) inhibits osteoclastogenesis, promotes osteogenesis and ameliorates bone loss in ovariectomized mice.Animal Model:C57BL/6 female mice (8 weeksd; 20-25 g) were removed bilateral ovaries
Dosage:30 mg/kg
Administration:I.p. for 6 weeks
Result:Attenuated bone loss by inhibiting osteoclast activation and promoting osteogenesis in ovariectomized mice.
体外研究：
Neobavaisoflavone (1-50 μM; 20 h) decreases NO (ED50=25 μM) and cytokine (ED50s=23.11, 5.03, 5.23, 5.26 and 18.80 μM for IL-1β, IL-6, IL-12p40, IL-12p70 and TNF-α, respectively) production in LPS plus IFN-γ-stimulated RAW264.7 macrophages.Neobavaisoflavone (1-100 μM; 30 min) decreases the chemiluminescence in PMA-stimulated RAW264.7 macrophages, with an ED50 of 19.94 μM in activated RAW264.7 cells.Neobavaisoflavone (1-100 μM); 20 h) has no effect on the viability and is not toxic to RAW264.7 cells.Neobavaisoflavone (20-50 μM; 48 h) inhibits prostate cancer cell proliferation by inducing cytotoxicity and apoptosis in a dose-dependent manner.Neobavaisoflavone (2-8 μM; 7 d) inhibitsRANKL‐mediated osteoclastogenesis in bone marrow monocytes (BMMCs) and RAW264.7 cells dose dependently at the early stage.
Neobavaisoflavone, a flavonoid, is isolated from the seeds of Psoralea corylifolia. Neobavaisoflavone exhibits anti-inflammatory, anti-cancer and anti-oxidation activities. Neobavaisoflavone inhibits DNA polymerase at moderate to high concentrations. Neobavaisoflavone also inhibits platelet aggregation.
体内研究：
Neobavaisoflavone (30 mg/kg; i.p. for 6 weeks) inhibits osteoclastogenesis, promotes osteogenesis and ameliorates bone loss in ovariectomized mice.Animal Model:C57BL/6 female mice (8 weeksd; 20-25 g) were removed bilateral ovaries
Dosage:30 mg/kg
Administration:I.p. for 6 weeks
Result:Attenuated bone loss by inhibiting osteoclast activation and promoting osteogenesis in ovariectomized mice.
体外研究：
Neobavaisoflavone (1-50 μM; 20 h) decreases NO (ED50=25 μM) and cytokine (ED50s=23.11, 5.03, 5.23, 5.26 and 18.80 μM for IL-1β, IL-6, IL-12p40, IL-12p70 and TNF-α, respectively) production in LPS plus IFN-γ-stimulated RAW264.7 macrophages.Neobavaisoflavone (1-100 μM; 30 min) decreases the chemiluminescence in PMA-stimulated RAW264.7 macrophages, with an ED50 of 19.94 μM in activated RAW264.7 cells.Neobavaisoflavone (1-100 μM); 20 h) has no effect on the viability and is not toxic to RAW264.7 cells.Neobavaisoflavone (20-50 μM; 48 h) inhibits prostate cancer cell proliferation by inducing cytotoxicity and apoptosis in a dose-dependent manner.Neobavaisoflavone (2-8 μM; 7 d) inhibitsRANKL‐mediated osteoclastogenesis in bone marrow monocytes (BMMCs) and RAW264.7 cells dose dependently at the early stage.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备